---
source_pdf: "https://drive.google.com/file/d/18Fj4DUB8tJx1HnD_jKm_M3NZPT2BeNVvSN621uslQdM/view"
drive_folder: "Portfolio/Evvy"
type: portfolio
company: Evvy
ingested: 2025-12-27
original_filename: "Evvy Presentation"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/18Fj4DUB8tJx1HnD_jKm_M3NZPT2BeNVvSN621uslQdM/view)

## Slide 1: Building the tracks: Data acquisition → insights

Building the tracks:
Data acquisition → insights

## Slide 2: Company Overview

| Company    | Description                                                                 | Value to provider/patient                                     | Making data research-grade                                                                              | Generating insights (internal or for partners)         | Lessons for Evvy                                                            |
| :--------- | :-------------------------------------------------------------------------- | :------------------------------------------------------------ | :------------------------------------------------------------------------------------------------------ | :----------------------------------------------------- | :-------------------------------------------------------------------------- |
| Flatiron   | Oncology EMR, curating data and selling to pharma                           | RCM / oncology guidelines are top features for physicians     | 1,500 part-time oncology nurses cleaning EMR data                                                       | Label expansion, HEOR studies, market access           | Value can be simple!                                                        |
| Tempus     | CLIA lab + data warehouse for AMCs                                          | Reference lab for oncology testing                            | Exploring other genes in panel, De-identification of medical records, linking imaging + genomic         | Drug discovery (limited today)                         | IVD is a hook, but easy to get labeled as IVD company                       |
| Evidation  | ~500K patients for on-demand wearable studies                               | Episodic nature of engagement limits value to patients        | ML mostly on quality control side (conformance, completeness, plausibility)                             | Symptom tracking                                       | Symptom tracking without closing the loop provides limited value            |
| Invitae    | Pure IVD company, acquired Ciitizen for digital capabilities ($325M!)     | Insights from Dx - mostly in NIPT, rare, carrier screening today | Enhancing variant interpretation (Jungla)                                                               | Reports to providers and patients                      | Invitae is playing catch up. Evvy was born with patient-first mentality     |
| 23andMe    | Consumer genetics company masquerading as drug discovery co.               | Unclear - may be detrimental                                  | GWAS / PheWAS analysis                                                                                  | Drug discovery (limited today)                         | Tough to balance information vs. recommendations                            |

## Slide 3: Funding and milestones

### Flatiron
*   Series A: $8M → build software
*   Series B: $130M → acquire EMR + hiring nurses

### Tempus
*   Series A: $10M → develop IVD
*   Series B: $50M → build data warehouse capabilities

### Evidation
*   Series A: $6M → quantify impact of digital health tools
*   Series B: $15M → start selling to biopharma

### Invitae
*   Series A: $5.9M → spin-out CLIA lab from tools business
*   Series B: $29.6M → prepare for hereditary cancer launch

### 23andMe
*   Series A: $9M → providing info only ($1000/test; Illumina recently acquired Solexa)
*   Series B: $27.8M → Post-ancestry partnership, studies on common traits (hair/eye color, freckles)